Neoadjuvant therapy (neoTx) has dramatically improved the prognosis of patients with locally advanced and borderline resectable pancreatic ductal adenocarcinoma, yet its mechanisms of action on tumor cells and the tumor microenvironment are still unknown.
Here, we aimed to characterize the multiple facets of neoTx-induced alterations in the pancreatic cancer microenvironment. Read more . . .